SBC is delighted to welcome Santo BioPharma to SBC

Santo Therapeutics is an innovative drug development company dedicated to advancing the next generation of lentiviral vector (LV) recombinant technology for in vivo gene therapy.

With over 20 years of expertise in vector optimiSation and disease mechanism research, their research results have been published in esteemed international journals. In the field of cancer treatment, Santo employs gene-based natural therapies to reprogram cellular self-protection mechanisms.

Dr. Luke Zhou, CEO & Founder, Santo Therapeutics Ltd:
“We are thrilled to join the vibrant community at Stevenage Bioscience Catalyst, where innovation and collaboration are at the heart of scientific progress. As Santo Therapeutics advances its gene therapy pipeline, being part of SBC offers invaluable access to cutting-edge infrastructure, a world-class network, and a shared mission to accelerate life-changing treatments. We look forward to contributing to and growing within this dynamic ecosystem.”

Find out more via the Santo Biopharma website here.